Improving OTIF in Pharmaceutical Supply Chains

This document is a guide that discusses the significant decline in on-time, in-full (OTIF) rates for pharmaceutical manufacturers since the onset of the COVID-19 pandemic, as reported by IDC. The guide outlines findings from a survey of over 500 companies in the pharma supply chain, revealing that two-thirds have lost effective demand forecasting capabilities. It details the challenges faced by the industry, including increased production costs, drug shortages, and degraded service levels. The guide emphasizes the necessity for companies to adopt patient-centric supply chain strategies to enhance resilience. Recommendations for achieving a patient-centric supply chain include evaluating technology gaps, deploying agile processes, ensuring holistic responses to disruptions, and utilizing third-party networks for collaboration. The guide stresses that a company-wide vision focused on patient needs is essential for effective supply chain management.